Changes in apolipoprotein AI after treatment with high-dose medroxyprogesterone acetate.
21 women (mean age 60 years, range 48-72) were given depot medroxyprogesterone acetate (DMPA), 1,000 mg/week parenterally for 6 months, as part of the treatment for endometrial carcinoma in either clinical stage I or II. Before treatment and after 1, 3 and 6 months of treatment serum apolipoprotein AI was analyzed by electroimmunoassay. There was a significant decrease in apolipoprotein AI after the administration of DMPA, compared to the value before treatment. A low level of apolipoprotein AI is considered a risk factor for the development of atherosclerosis and cardiovascular disease. Such a risk might therefore be anticipated if the period of treatment was extended to several years.
D000368:Aged; D016632:Apolipoprotein A-I; D001053:Apolipoproteins / Q000097:blood*; D003692:Delayed-Action Preparations; D003864:Depression, Chemical; D005260:Female; D006801:Humans; D007118:Immunoassay; D008075:Lipoproteins, HDL / Q000097:blood*; D008525:Medroxyprogesterone / Q000031:analogs & derivatives* / Q000627:therapeutic use; D017258:Medroxyprogesterone Acetate; D008875:Middle Aged; D013997:Time Factors; D014594:Uterine Neoplasms / Q000097:blood / Q000188:drug therapy*
D016632:Apolipoprotein A-I; D001053:Apolipoproteins; D003692:Delayed-Action Preparations; D008075:Lipoproteins, HDL; D017258:Medroxyprogesterone Acetate; D008525:Medroxyprogesterone